We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+45.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$396M
AUM Growth
+$81.5M
(+26%)
Cap. Flow
-$53.8M
Cap. Flow
% of AUM
-13.59%
Top 10 Holdings %
Top 10 Hldgs %
82.26%
Holding
45
New
14
Increased
6
Reduced
5
Closed
12
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
1.9
quarters
Top 20 Avg Time Held Equity + Options
1.7
quarters
Avg Time Held Equity only
2.1
quarters
Top 10 Avg Time Held Equity only
2.1
quarters
Top 20 Avg Time Held Equity only
2.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
+$12.6M |
| 2 |
CytomX Therapeutics
CTMX
|
+$10.5M |
| 3 |
Fate Therapeutics
FATE
|
+$9.28M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$7.47M |
| 5 |
Tempest Therapeutics
TPST
|
+$5.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$19.8M |
| 2 |
Ardelyx
ARDX
|
+$18.6M |
| 3 |
Kyntra Bio
KYNB
|
+$15.7M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$15M |
| 5 |
Editas Medicine
EDIT
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.89% |
| 2 | Miscellaneous | 14.11% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Assembly Biosciences
ASMB
$414M
| $75M | 18.97% |
245,264
| – | – |
2014 Q4
9 quarters
|
|
2
Ironwood Pharmaceuticals
IRWD
$593M
| $49.6M | 12.53% |
3,469,185
+59,700
| +2% | +$816K |
2015 Q4
5 quarters
|
|
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $47.5M | 12.01% |
551,041
-10,300
| -2% | -$742K |
2015 Q4
5 quarters
|
|
4
CALL
Gilead Sciences
GILD
$183B
| $34M | 8.59% |
+500,000
| New | +$35.2M |
2017 Q1
0 quarters
|
|
5
Ascendis Pharma A/S
ASND
$14.7B
| $28.7M | 7.26% |
1,025,700
+50,000
| +5% | +$1.26M |
2016 Q3
2 quarters
|
|
6
Kura Oncology
KURA
$874M
| $23M | 5.81% |
2,611,906
| – | – |
2015 Q4
5 quarters
|
|
|
7
Aclaris Therapeutics
ACRS
$511M
| $20.1M | 5.07% |
673,100
+259,100
| +63% | +$7.47M |
2016 Q4
1 quarter
|
|
|
8
CytomX Therapeutics
CTMX
$508M
| $13.7M | 3.47% |
+794,969
| New | +$10.5M |
2017 Q1
0 quarters
|
|
|
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $12.4M | 3.14% |
+3,000,000
| New | +$12.6M |
2017 Q1
0 quarters
|
|
|
10
Fate Therapeutics
FATE
$240M
| $11.5M | 2.92% |
+2,537,026
| New | +$9.28M |
2017 Q1
0 quarters
|
|
11
Atara Biotherapeutics
ATRA
$93.4M
| $8.94M | 2.26% |
17,392
+8,760
| +101% | +$3.63M |
2016 Q4
1 quarter
|
|
12
aTyr Pharma
ATYR
$19.7M
| $8.02M | 2.03% |
163,761
+93,976
| +135% | +$4.3M |
2016 Q4
1 quarter
|
|
|
13
Tempest Therapeutics
TPST
$11.5M
| $6.57M | 1.66% |
+1,201
| New | +$5.59M |
2017 Q1
0 quarters
|
|
|
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $5.68M | 1.44% |
+258,457
| New | +$5.48M |
2017 Q1
0 quarters
|
|
15
Xencor
XNCR
$1.75B
| $5.62M | 1.42% |
234,813
-140,187
| -37% | -$3.38M |
2016 Q4
1 quarter
|
|
|
KIN
16
DELISTED
Kindred Biosciences, Inc.
KIN
| $3.84M | 0.97% |
544,880
-26,246
| -5% | -$164K |
2014 Q4
9 quarters
|
|
|
NBRV
17
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $3.18M | 0.8% |
1,059
| – | – |
2015 Q3
6 quarters
|
|
18
DELISTED
Regulus Therapeutics
RGLS
| $2.49M | 0.63% |
+12,583
| New | +$2.39M |
2017 Q1
0 quarters
|
|
19
DELISTED
Adverum Biotechnologies
ADVM
| $2.36M | 0.6% |
87,445
| – | – |
2016 Q3
2 quarters
|
|
|
ARAV
20
DELISTED
Aravive, Inc. Common Stock
ARAV
| $2.13M | 0.54% |
+16,667
| New | +$1.76M |
2017 Q1
0 quarters
|
|
|
VIVE
21
DELISTED
VIVEVE MED INC
VIVE
| $1.58M | 0.4% |
+250
| New | +$1.22M |
2017 Q1
0 quarters
|
|
22
Agios Pharmaceuticals
AGIO
$1.8B
| $1.36M | 0.34% |
23,300
| – | – |
2016 Q3
2 quarters
|
|
|
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.3M | 0.33% |
+382,000
| New | +$1.08M |
2017 Q1
0 quarters
|
|
|
24
Kyntra Bio
KYNB
$23.8M
| $1.04M | 0.26% |
1,680
-25,767
| -94% | -$15.7M |
2014 Q4
9 quarters
|
|
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.01M | 0.26% |
6,360
| – | – |
2016 Q3
2 quarters
|
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q1 2017 Portfolio in Review
As of Q1 2017, EcoR1 Capital held 45 positions worth $396M, up 26% from $314M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
EcoR1 Capital withdrew a net $53.8M in Q1 2017, closing 12 positions and reducing 5 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, EcoR1 Capital opened a new position in Cascadian Therapeutics, Inc. worth $12.4M.
- EcoR1 Capital's largest Q1 2017 buy was Cascadian Therapeutics, Inc.: 3,000,000 shares worth $12.4M.
- EcoR1 Capital added most to Aclaris Therapeutics in Q1 2017, an estimated $7.47M increase.
- EcoR1 Capital's biggest Q1 2017 reduction was Kyntra Bio, cutting an estimated $15.7M.
- EcoR1 Capital fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $19.8M.
- EcoR1 Capital's ten largest holdings make up 82% of its $396M portfolio in Q1 2017.
- EcoR1 Capital opened 14 new positions and closed 12 in Q1 2017.
- EcoR1 Capital's portfolio value rose 26% quarter-over-quarter to $396M.
Based on EcoR1 Capital's 13F filing for Q1 2017, filed 15 May 2017.